The Endobal™ Research Program is a privately funded, participant-supported initiative conducting real-world studies to evaluate Endobal™'s potential in delaying the onset, slowing the progression, and extending the lifespan of individuals diagnosed with ALS. Unlike traditional trials, this program excludes placebo controls, prioritizing direct patient outcomes. By leveraging real-world data, it aims to advance scientific understanding and provide actionable insights for managing this neurodegenerative disease, offering hope through evidence-based exploration of therapeutic interventions.
What Is 
?
All Natural - Alcohol-Free - Non-Intoxicating - Easy Dosing - No Artificial Colors or Flavors
World's First Therapy For ALS Targeting The Endocannabinoid System
Endobal™ represents the first therapy that directly targets the endocannabinoid system in patients with amyotrophic lateral sclerosis (ALS), a progressive neuro‑degenerative disease that compromises muscle control and respiratory function. By modulating the body’s own cannabinoid receptors, Endobal™ aims to reduce neuroinflammation, protect motor neurons, and improve symptom management, offering a novel mechanism of action that differs from traditional ALS treatments which focus mainly on symptom relief and slowing disease progression through non‑cannabinoid pathways. Clinical studies currently underway assess its safety, tolerability, and efficacy, and early results suggest that engaging the endocannabinoid system may provide measurable benefits in motor function and quality of life. As the inaugural agent of its kind, Endobal™ holds the promise of expanding therapeutic options for the ALS community and underscores the growing relevance of cannabinoid‑based research in neurodegenerative disorders.
Endobal™ is a meticulously engineered blend of phytocannabinoids dissolved in a medium‑chain triglyceride (MCT) oil carrier, formulated expressly to engage the body’s endocannabinoid system in the context of amyotrophic lateral sclerosis (ALS). By delivering a spectrum of plant‑derived cannabinoids at precise concentrations, the product seeks to modulate neuro‑inflammatory pathways, support neuronal homeostasis, and potentially alleviate the muscle spasticity and pain that commonly accompany ALS progression. The MCT oil base enhances bioavailability, allowing the active compounds to cross the blood‑brain barrier more efficiently while offering a stable, oil‑soluble medium that resists oxidation. In presenting a scientifically grounded approach, Endobal™ aims to complement existing therapeutic regimens, providing a novel, adjunctive option for individuals living with ALS and their caregivers.
Endobal™ harnesses naturally occurring phytocannabinoids to engage the body’s endocannabinoid system, a pivotal regulator of cellular signaling that is increasingly recognized for its role in amyotrophic lateral sclerosis (ALS). By modulating this system, the formulation delivers neuroprotective effects that help preserve motor neuron integrity, while simultaneously dampening inflammatory pathways and scavenging free radicals through potent antioxidant activity. In addition, Endobal™ exerts fine‑tuned control over glutamate dynamics, preventing the excess excitatory signaling that can exacerbate neuronal damage. Together, these mechanisms create a comprehensive therapeutic profile that supports cellular health, reduces oxidative stress, and mitigates the progressive decline characteristic of ALS.
Endobal™ Research Study Project
About Our Research Study Program
A private research study for amyotrophic lateral sclerosis (ALS) is an investigative project that is initiated, funded, and overseen by non‑governmental entities such as universities, independent research institutes, charitable foundations, or biotech companies. Its primary goal is to deepen scientific understanding of ALS—ranging from the disease’s underlying genetic and molecular mechanisms to potential therapeutic approaches—while often focusing on specific hypotheses or novel technologies that may not yet be part of larger, publicly‑backed programs. Because the study is privately organized, the investigators have greater flexibility in designing protocols, selecting participant eligibility criteria, and tailoring data‑collection methods to suit the particular scientific questions they aim to answer. Participants typically enroll voluntarily, providing informed consent after receiving clear explanations of the study’s purpose, procedures, potential risks, and benefits. Confidentiality of personal health information is rigorously maintained, and the study’s findings are usually shared through peer‑reviewed journals or scientific conferences, contributing to the broader body of ALS knowledge. While private studies may sometimes lead to the development of new treatments that later progress to larger clinical trials, they are distinct from routine clinical care or public‑sector trials in that they are driven by the specific interests and resources of the sponsoring organization rather than by national health agencies. Ultimately, a private research study for ALS represents a focused, collaborative effort to accelerate discovery and improve outcomes for individuals living with this challenging neurodegenerative disease.
A participant-funded research study for ALS (amyotrophic lateral sclerosis) is a type of clinical or scientific investigation in which individuals affected by the disease—often patients or their families—directly contribute financially to support the research. Unlike traditional studies that rely on funding from institutions, foundations, or pharmaceutical companies, participant-funded studies are driven by personal investments from those seeking new treatments or a better understanding of ALS. These contributions may cover various aspects of the research, such as laboratory testing, data analysis, or participation in experimental therapies. This model empowers patients to take an active role in advancing research, particularly in cases where funding is limited or where novel approaches may not yet attract larger sponsors. While participants are deeply involved, they are typically guided by qualified researchers or medical professionals to ensure scientific rigor and ethical standards. It’s important for individuals considering such involvement to fully understand the study’s goals, risks, and potential benefits, and to consult with healthcare providers before making financial or medical commitments.
A non-placebo research study for ALS (amyotrophic lateral sclerosis) is a type of clinical trial in which all participants receive the investigational treatment being studied, rather than some participants receiving an inactive substance, or placebo. In traditional clinical trials, researchers often use a placebo group to compare outcomes and determine whether the treatment has a meaningful effect beyond standard care or psychological expectation. However, in a non-placebo design, every individual enrolled in the study is administered the active therapy, which can be particularly important in conditions like ALS that are rapidly progressive and currently have limited treatment options. This approach is often chosen to ensure that all participants have access to the potential benefits of the experimental therapy, especially when treating a severe and life-altering disease. Instead of using a placebo control, researchers may compare the results of the current study to previously collected data from similar ALS patients, known as a natural history or external control group, to evaluate whether the treatment leads to improved outcomes. While non-placebo studies can raise challenges in objectively measuring treatment efficacy due to the lack of a concurrent control group, they are often considered ethically favorable because they eliminate the possibility of withholding a potentially beneficial therapy from participants facing a serious condition. These studies play a crucial role in accelerating the development of new ALS treatments while prioritizing participant welfare.